CICADEA BIOTECH, LLC

Medtech · Private

Non-invasive urine-based biomarker screening test for early detection of kidney cancer and molecular residual disease monitoring

Grants
$305K
1 award
Sector median: 1
Raised
—
No Form D on record
Contracts
—
No federal contracts on record
Patents
5
0 granted · 5 pending
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Federal grantNational Science Foundation · Phase I · STTR Phase I: A Urine Test for Kidney Cancer Detection$305,000
Federal grant · SBIR/STTR

Peer position

Medtech · 4531 companies · ranked on federal contract value
Medtech companies ranked by federal contract value
#CompanyContractsDisclosed equity
2203TRANSLUCENCE BIOSYSTEMS, INC.——
2204NanoSoft, LLC——
2205POLARITYTE MD, INC.——
2206CICADEA BIOTECH, LLC——
2207MICROCURES INC——
2208BAY GENOMICS, LLC——
2209COGNIFISENSE, INC.——

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Patents

USPTO · 0 granted of 5
  • Kidney Cancer Screening Methodsapplication
  • Kidney Cancer Screening Methodsapplication
  • Process For Identifying And Quantifying Nucleic Acid Sequences From Live Microorganismsapplication
  • Novel Urinary Biomarker For Kidney Cancer Screeningapplication
  • Process for identifying and quantifying nucleic acid sequences from live microorganismsapplication

Regulatory activity · Medtech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.